Flu, also known as influenza, is a contagious viral illness that can cause mild to severe symptoms and even death in healthy individuals. It is spread through coughing and sneezing, contact with surfaces contaminated by flu virus particles, and through the skin. The virus can be passed from one person to another for a week or longer. People with pre-existing health conditions are at risk for complications due to influenza. The influenza virus belongs to the family of Orthomyxoviridae. Its genome consists of segmented negative-sense single-strand RNA. There are four genera in this family, although only influenza A and B are clinically relevant to humans. Influenza A and B viruses contain three polymerase proteins, called HA, HA2, and HA3. The vaccine is most effective when the circulating influenza viruses match the ones in the vaccination. This means that vaccines must be updated every two years to reflect current influenza strains. It is important for individuals who are at high risk to be immunized each year.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/2443
Influenza Therapeutics Market: Drivers
Increasing approvals of drug for the treatment of influenza is expected to drive the influenza therapeutics market growth. For instance, in October 2018, Roche announced that the U.S. Food and Drug Administration (FDA) approved Xofluza (TM) (baloxavir marboxil) for the treatment of acute, uncomplicated influenza or flu, in people 12 years of age and older.
Growing number of clinical pipeline studies is driving the influenza therapeutics market growth during the forecast period. For instance, in January 2018, Romark Laboratories L.C. initiated the phase 3 clinical trial for Nitazoxanide to evaluate its efficacy and safety in the treatment of uncomplicated influenza. Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral drug, used in the treatment of intestinal parasitic infections caused by Cryptosporidium parvam and Giardia lamblia. This study is expected to be completed in April 2019.
Moreover, in November 2018, Henry M. Jackson Foundation for the Advancement of Military Medicine, initiated phase 4 clinical trial study for egg-based influenza vaccines to study the realistic evaluation of influenza vaccine effectiveness in active duty members, military retirees, and other Department of Defense (DOD) beneficiaries.
Furthermore, growing initiatives by various sponsors to conduct phase 1 clinical trial to study the safety parameter of anti-influenza drugs is expected to drive the market growth. For instance, in October 2018, Emory University started phase 1 clinical trial for seasonal influenza vaccine. The study has been designed to evaluate the impact of imprinting and repeated influenza vaccination on adaptive immunity, transcriptomics, and metabolomics. The study is expected to be completed in July 2020.
Influenza Therapeutics Market: Restraints
Factor such as relatively long production times, limited vaccine capacity, moderate efficacy in certain people, and lack of cross-reactivity, is projected to restrain growth of the influenza therapeutic market during the forecast period. Moreover, rising concerns among people regarding the side effects of vaccines is again expected to hamper growth of the influenza therapeutic market. For instance, in October 2018, according to the National Opinion Research Centre (NORC) at the University of Chicago survey, around 43% of the adults were vaccinated and 14% plans to receive the flu shot. However, around 41% of the American people reported that they are not vaccinated and do not intend to get vaccinated, as adults were most likely to cite concerns about side effects of the vaccine.
Influenza Therapeutics Market: Regional Analysis
On the basis of region, the global influenza therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America holds leading position in the market, due to high presence of key players such as GlaxoSmithKline plc and Hoffmann-La Roche Ltd. The regulatory agencies in the region select influenza viruses that are required for developing the influenza vaccine. In March 2018, FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) conducted a meeting to select the influenza viruses for the composition of the influenza vaccine. In the meeting, VRBPAC recommended the trivalent formulation of influenza vaccines for influenza A including A/Michigan/45/2015 (H1N1) pdm09-like virus, A/Singapore/INFIMH-16–0019/2016 (H3N2)-like virus, and B/Colorado/06/2017-like virus (B/Victoria lineage). The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain: a B/Phuket/3073/2013-like virus (B/Yamagata lineage).
Asia Pacific is also expected to witness significant growth in the influenza therapeutics market, due to growing initiatives by the Asia-Pacific Alliance for the Control of Influenza (APACI), to reduce the burden of influenza by enhancing control measures and boosting pandemic preparedness in the region, through the provision of educational information and activities.
Europe have also gained significant position in the market, due to growing initiatives by European Medical Association (EMA) during an influenza pandemic season leading to continuous monitoring of safety of centrally authorized pandemic influenza vaccines and antiviral medicines, and fast-track review of data for the authorization of pandemic influenza vaccines for use in all EU Member States. Also, growing number of public awareness programs for the prevention and diagnosis of influenza resulted in significant growth of the influenza therapeutics market in this region.
Key players operating in the global influenza therapeutic market include Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd., BiondVax Pharmaceuticals Ltd., Atriva Therapeutics Gmbh, Texas Medical Center, Life Science Austria (LISA), GE Healthcare Life Sciences, Sanofi Pasteur SA and Mylan, Inc.
Request Here PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2443
Influenza Therapeutics Market: Taxonomy
By Drug Type
- Antivirals
- Oseltamivir
- Zanamivir
- Peramivir
- Baloxavir Marboxil
- Vaccine
- Quadrivalent Flu Vaccines
- Trivalent Flu Vaccines
By Virus Type
- Influenza Virus Type- A
- Influenza Virus Type-B
By Age Group
- Pediatrics
- Adult
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Direct Buy This Premium Research Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2443
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Influenza Therapeutics Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Influenza Therapeutics Industry Impact
Chapter 2 Global Influenza Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Influenza Therapeutics (Volume and Value) by Type
2.3 Global Influenza Therapeutics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Influenza Therapeutics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Influenza Therapeutics Market Analysis
Chapter 6 East Asia Influenza Therapeutics Market Analysis
Chapter 7 Europe Influenza Therapeutics Market Analysis
Chapter 8 South Asia Influenza Therapeutics Market Analysis
Chapter 9 Southeast Asia Influenza Therapeutics Market Analysis
Chapter 10 Middle East Influenza Therapeutics Market Analysis
Chapter 11 Africa Influenza Therapeutics Market Analysis
Chapter 12 Oceania Influenza Therapeutics Market Analysis
Chapter 13 South America Influenza Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Influenza Therapeutics Business
Chapter 15 Global Influenza Therapeutics Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
About US
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com